Henlius to Initiate P-III Study of HLX04-O (biosimilar- bevacizumab) in Australia
Shots:
- Henlius reported that TGA has approved the filing of clinical trial for HLX04-O to treat wet-AMD
- The two part P-III global study is expected to be initiated in Australia to further evaluate the efficacy & safety of HLX04-O (vitreous injection) in treatment of wAMD
- HLX04-O is a recombinant anti-VEGF humanized mAb ophthalmic injection and has the potential to be one of the first bevacizumab approved for ophthalmic diseases
Ref: Henlius | Image: Henlius
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com